Daraxonrasib Shows Antitumor Activity in Previously Treated RAS-Mutated Pancreatic Cancer
May 09, 2026
View online
Daraxonrasib Shows Antitumor Activity in Previously Treated RAS-Mutated Pancreatic Cancer
FDA Approved Zenocutuzumab-zbco for Advanced NRG1 Fusion-Positive Cholangiocarcinoma
OncoBillionaires 2026: 28 Billionaires Powering Innovation and Access Challenges
15 Posts Not To Miss From ASBrS2026
Professor Richard Sullivan: Building Cancer Systems Amidst Global Instability
Muna Al-Khaifi: Development and Launch of a New Quality Standard for Cancer Survivorship
Top Prostate Cancer Trials to Watch at ASCO 2026
Former NFL Prospect and South Carolina QB Stephen Garcia Diagnosed With Stage 4 Colon Cancer
The Voice of Oncology
Unsubscribe
|
Manage subscription
OncoDaily, P53 Inc.
867 Boylston Street, 5th Floor, Suite 1094, Boston, MA 02116
Copyright (C) 2023-2026. OncoDaily, P53 Inc. All rights reserved.
